CRO services within diabetes

Explore clinical endpoints in our diabetic mouse and rat models.

Get in touch

Please get in touch if you are interested in discussing how to get started with your study. Reach out to Director Michael Feigh mfe@gubra.dk Ph. +45 2382 9493

NOD mouse model

  • Standard mouse model of type 1 diabetes
  • Sustained hyperglycemia from ~8 weeks of age
  • Age-dependent transition to diabetes.
  • Well-defined progression in islet pathology
  • Treatment efficacy of various anti-diabetic drug classes

STZ mouse/rat model

  • Robust and stabile hyperglycemia
  • Fast and predictable induction of insulin deficiency
  • 100% response rate using medium-dose streptozotocin (STZ)
  • Weight-neutral effects in lean animals.
  • Similar diabetic phenotype in mice and rats
  • Treatment efficacy of insulins other anti-diabetic drug classes

Islets pancreatic of imaging 3D

Seeing is believing! Gubra has years of experience with pancreatic markers in preclinical models of diabetes. Analysis of beta cell dynamics in animal models of diabetes is key to understand therapeutic effects of anti-diabetic compounds. Gubra offers light sheet fluorescence microscopy-based 3D visualization and quantitation of pancreatic beta cell mass.

Types of studies

Acute efficacy studies

In an acute efficacy study we offer e.g.

 

  • OGTT/IPGTT/IVGTT and ITT in rats and mice
  • Automatized food intake testing
  • In vitro biology

Chronic efficacy studies

In a chronic efficacy study we offer e.g.

 

  • Long term effects on glucose homeostasis in ZDF rats
  • Chronic (7 days to 12+ weeks) efficacy testing
  • In-house developed and validated Glucose
  • Compound pancreatectomy model
  • Ex vivo assays (insulin, HbA1c, glucose, GLP-1, PYY etc.)

Mode of action studies

In a mode of action study we offer e.g.

 

  • Hyperinsulinemic euglycemic clamp studies
  • Lipogenesis
  • Lactate clamp
  • Gastric Bypass surgery
  • Energy expenditure
  • Insulin sensitivity testing (endogenous glucose production and tissue glucose uptake) using the hyperinsulinemic euglycemic clamp

Gubra in vivo study approach in diabetes

We have extensive experience of conducting preclinical diabetes studies in a variety of different rodent models of both type 1 and type 2 diabetes. We have a long track record of creating impact for our customers, when it comes to working with difficult models such as ZDF rats and db/db mice as well as quantitating beta-cell mass and other histological-pathological endpoints of diabetes.

Our scientific expertise within diabetes, combined with our long-standing CRO experience, provide solid data on which to base decisions. Furthermore, we have a high availability of animal models enabling us to accelerate studies.

Related Links:

Main offerings

 

  • Extensive experience with the majority of commercially available rodent models (C57BL/6, ob/ob, db/db mice as well as SPD and ZDF rats).
  • Oral/intravenous/intraperitoneal glucose tolerance tests (OGTT, IVGTT, IPGTT) and insulin tolerance test (ITT).
  • Continuous (24h) glucose monitoring in rats.
  • Insulin sensitivity testing (endogenous glucose production and tissue glucose uptake) using hyperinsulinemic euglycemic clamp.
  • NOD mice and models of pancreatectomy.
  • RNA sequencing and bioinformatics.
  • Glucose infusion study.
  • Hyperinsulinemic-euglycemic clamp.

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Michael Feigh

Director

mfe@gubra.dk
+45 2382 9493